An economic analysis of the cost of mobile units for harm reduction, naloxone distribution, and medications for opioid use disorder

被引:0
|
作者
Castry, Mathieu [1 ]
Tin, Yjuliana [2 ]
Feder, Noah M. [3 ]
Lewis, Nikki [4 ]
Chatterjee, Avik [4 ,5 ]
Rudorf, Maria [4 ]
Samet, Jeffrey H. [4 ,5 ]
Beers, Donna [4 ]
Medley, Bethany [6 ]
Gilbert, Louisa [6 ]
Linas, Benjamin P. [1 ,5 ]
Barocas, Joshua A. [2 ]
机构
[1] Boston Med Ctr, Sect Infect Dis, Boston, MA USA
[2] Univ Colorado, Div Gen Internal Med & Infect Dis, Sch Med, 12631 E 17th Ave,Mailstop B180, Aurora, CO 80045 USA
[3] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[4] Boston Med Ctr, Sect Gen Internal Med, Boston, MA USA
[5] Boston Univ, Chobanian & Avedisian Sch Med, Boston, MA USA
[6] Columbia Univ, Sch Social Work, Social Intervent Grp, New York, NY USA
来源
JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT | 2024年 / 167卷
基金
美国国家卫生研究院;
关键词
Mobile health units; Opioid use disorder; Harm reduction; Medications for opioid use disorder; Economic evaluation; OVERDOSE; MASSACHUSETTS; BUPRENORPHINE; PROGRAM; IMPACT; STATES;
D O I
10.1016/j.josat.2024.209517
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background & objective: Mobile substance use treatment units are effective approaches to increase treatment access and reduce barriers to opioid use disorder (OUD) care. However, little is known about the economic costs of maintaining and operating these units. This study aimed to estimate the economic costs of starting and maintaining mobile units providing harm reduction, overdose education and naloxone distribution (OEND), and medication for opioid use disorder (MOUD). Methods: As part of the HEALing Communities Study, four communities in Massachusetts (Bourne/Sandwich, Brockton, Gloucester, Salem) implemented mobile units offering OEND and MOUD (buprenorphine and naltrexone only); each selected different services tailored to their community. All provided MOUD linkage via telehealth, but only one offered in-person MOUD prescribing on the unit. We retrospectively collected detailed resource utilization data from invoices to estimate the direct economic costs from August 2020 through June 2022. Cost components were categorized into start-up and operating costs. We calculated total economic cost over the study period and the average monthly operating cost. Results: Implementing a mobile unit offering OEND and MOUD required a one-time median start-up cost of $59,762 (range: $52,062-$113,671), with 80 % of those costs attributed to the vehicle purchase. The median monthly operating cost was $14,464. The largest cost category for all mobile units was personnel costs. The monthly ongoing costs varied by community settings and services: approximately $5000 for two urban communities offering OEND and MOUD linkage via telehealth (Gloucester, Salem), $28,000 for a rural community (Bourne/Sandwich), and $23,000 for an urban community also providing in-person MOUD prescribing on the unit (Brockton). Conclusion: The economic costs of mobile substance use treatment and harm reduction units are substantial but vary by community settings and services offered. Our results provide valuable community-level economic data to stakeholders and policymakers considering establishing and/or expanding mobile units with OEND and MOUD services. Further exploration of cost-effectiveness and efficiency should be considered across different settings.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis
    Priest, Kelsey C.
    King, Caroline A.
    Englander, Honora
    Lovejoy, Travis, I
    McCarty, Dennis
    SUBSTANCE ABUSE, 2022, 43 (01) : 1251 - 1259
  • [32] Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type
    Hayes, Corey J.
    Raciborski, Rebecca A.
    Nowak, Matthew
    Acharya, Mahip
    Nunes Jr, Edward V.
    Winhusen, T. John
    ADDICTION, 2025, 120 (01) : 138 - 151
  • [33] Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis
    Socias, M. Eugenia
    Choi, Jin Cheol
    Fairbairn, Nadia
    Johnson, Cheyenne
    Wilson, Dean
    Debeck, Kora
    Brar, Rupinder
    Hayashi, Kanna
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2023, 118
  • [34] Comparative Analysis of Instrumental Variables on the Assignment of Buprenorphine/Naloxone or Methadone for the Treatment of Opioid Use Disorder
    Homayra, Fahmida
    Enns, Benjamin
    Min, Jeong Eun
    Kurz, Megan
    Bach, Paxton
    Bruneau, Julie
    Greenland, Sander
    Gustafson, Paul
    Karim, Mohammad Ehsanul
    Korthuis, P. Todd
    Loughin, Thomas
    Maclure, Malcolm
    Mccandless, Lawrence
    Platt, Robert William
    Schnepel, Kevin
    Shigeoka, Hitoshi
    Siebert, Uwe
    Socias, Eugenia
    Wood, Evan
    Nosyk, Bohdan
    EPIDEMIOLOGY, 2024, 35 (02) : 218 - 231
  • [35] Suicide within 1 year of non-fatal overdose: Risk factors and risk reduction with medications for opioid use disorder
    Nowels, Molly A.
    Duberstein, Paul R.
    Crystal, Stephen
    Treitler, Peter
    Miles, Jennifer
    Olfson, Mark
    Samples, Hillary
    GENERAL HOSPITAL PSYCHIATRY, 2024, 86 : 24 - 32
  • [36] Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use Disorder
    Shulman, Matisyahu
    Luo, Sean X.
    Campbell, Aimee N. C.
    Scodes, Jennifer
    Pavlicova, Martina
    Broffman, Andi
    Saxon, Andrew J.
    Nunes, Edward, V
    JOURNAL OF ADDICTION MEDICINE, 2020, 14 (05) : E188 - E194
  • [37] Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States
    Hochheimer, Martin
    Unick, George Jay
    ADDICTIVE BEHAVIORS, 2022, 124
  • [38] High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units
    Valencia, Jorge
    Alvaro-Meca, Alejandro
    Troya, Jesus
    Cuevas, Guillermo
    Gutierrez, Jorge
    Morro, Angela
    Alvarez, Jorge
    Pulido, Laura
    Canamares, Irene
    Escobar, Ismael
    Moreno, Santiago
    Ryan, Pablo
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 72 : 181 - 188
  • [39] Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids
    Winhusen, Theresa
    Wilder, Christine
    Lyons, Michael S.
    Theobald, Jeff
    Kropp, Frankie
    Lewis, Daniel
    DRUG AND ALCOHOL DEPENDENCE, 2020, 216
  • [40] Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis
    Solomon, Keisha T.
    Bandara, Sachini
    Reynolds, Ian S.
    Krawczyk, Noa
    Saloner, Brendan
    Stuart, Elizabeth
    Connolly, Elizabeth
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2022, 132